Report Overview

The UK Transthyretin Amyloidosis (ATTR) Therapeutics market size stood at around USD 0.012 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Transthyretin Amyloidosis (ATTR) is caused by the transthyretin (TTR) protein and occurs in two forms, either hereditary or wild type. Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. The United Kingdom has the lowest prevalent population in 2016.

Till 2019, 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V122I variant (V122I-hATTR-CM), and 118 with non-V122I-hATTR-CM at the UK National Amyloidosis Centre were studied. Patients with V122I-hATTR-CM were more impaired functionally and had worse measures of cardiac disease at the time of diagnosis, a greater decline in quality of life, and poorer survival in comparison with the other subgroups.



Market Growth Drivers

The growth will be driven by the surge in the development of drug therapies of varying mechanisms, and the overall rise in diagnosed patient population due to a much-needed increase in awareness and understanding of the disease among clinicians and the public.

The main driver of the ATTR market expansion will be the approval and launch of the RNA interference therapeutics for both ATTR polyneuropathy and ATTR cardiomyopathy. Another prominent contributor to sales growth is the increase in diagnosed prevalence, the increase will be caused by improved understanding and awareness of the disease alongside campaigns by drug developers to increase genetic testing.

The ATTR market currently has unlimited competition and holds room for new entrants.

The key market opportunities lie in addressing unmet needs through the development of efficacious therapies for clearing already deposited amyloid and increasing the number of therapies approved for ATTR cardiomyopathy.

Market Restraints

The major barrier for the ATTR market will be the huge annual cost of therapy for new pipeline drugs and the lack of options for advanced disease states, the stage at which the majority of patients are diagnosed.